Mark E. Saad - Sep 11, 2024 Form 4 Insider Report for Axsome Therapeutics, Inc. (AXSM)

Role
Director
Signature
/s/ Herriot Tabuteau, M.D., Attorney-in-Fact
Stock symbol
AXSM
Transactions as of
Sep 11, 2024
Transactions value $
-$965,442
Form type
4
Date filed
9/11/2024, 07:00 PM
Previous filing
Jun 11, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AXSM Common Stock Options Exercise $40.4K +11K +110.14% $3.67 21K Sep 11, 2024 Direct F1, F2
transaction AXSM Common Stock Sale -$1.01M -11K -52.41% $91.31 10K Sep 11, 2024 Direct F2, F3, F4
holding AXSM Common Stock 300 Sep 11, 2024 See explanation 5 below. F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AXSM Stock Option (Right to Buy) Options Exercise $0 -11K -100% $0.00 0 Sep 11, 2024 Common Stock 11K $3.67 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents an exercise of stock options prior to the 10-year expiration date of such options, which would occur later this month.
F2 Such transaction was pursuant to a pre-approved 10b5-1 plan.
F3 Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
F4 Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $90.25 and $92.90.
F5 Represents additional shares held indirectly by the Reporting Person prior to September 11, 2024 which includes shares indirectly beneficially owned by Mr. Saad as custodian for his children's UTMA accounts.